2cureX AB publishes annual report for the fiscal year 2017
The board and the Chief Executive Officer of 2cureX AB (”2cureX”) hereby publishes the annual report for the fiscal year 2017. The annual report and the accompanying auditor’s report is available via the attached file or on the company’s website (www.2curex.com). Please observe that the annual report is only available in Swedish.
Sedermera Fondkommission is the Certified Adviser of 2cureX.
For more information about 2cureX:
Ole Thastrup, CEO
Phone: +45 22 11 53 99
This information is information that 2cureX AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication on May 7th, 2018.
2cureX has developed IndiTreat® (Individual Treatment Design) – a patented method for selecting the right drug for the right patient, thereby improving cancer treatment. Initially, IndiTreat® is targeted towards colorectal cancer; but the method is applicable to additional cancer indications (e.g. ovarian, breast and kidney cancer). The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).